Edition:
India

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

82.79USD
18 Oct 2019
Change (% chg)

$0.41 (+0.50%)
Prev Close
$82.38
Open
$82.38
Day's High
$83.32
Day's Low
$82.03
Volume
2,292,783
Avg. Vol
1,463,599
52-wk High
$88.76
52-wk Low
$65.44

Select another date:

Wed, Jul 17 2019

Photo

Abbott hits record high as diabetes device fuels profit beat

Abbott Laboratories beat analysts' estimates for quarterly profit and lifted its full-year earnings forecast on Wednesday, boosted by a near 64% jump in sales of its blood sugar monitoring device.

UPDATE 2-Diabetes devices power Abbott's profit beat, forecast raise

July 17 Abbott Laboratories beat analysts' estimates for quarterly profit and lifted its full-year adjusted earnings forecast on Wednesday, as the company benefits from strong demand for its blood sugar monitoring devices.

Abbott to hike production of lower-cost glucose monitors as diabetes soars

CHICAGO Abbott Laboratories plans to ramp up manufacturing capacity for its lower-cost continuous glucose monitor, the FreeStyle Libre, by three to five times in the next few years, aiming to reach millions more patients worldwide, the company told Reuters.

Abbott to hike production of lower-cost glucose monitors as diabetes soars

CHICAGO Abbott Laboratories plans to ramp up manufacturing capacity for its lower-cost continuous glucose monitor, the FreeStyle Libre, by three to five times in the next few years, aiming to reach millions more patients worldwide, the company told Reuters.

FOCUS- Abbott to hike production of lower-cost glucose monitors as diabetes soars

CHICAGO, July 16 Abbott Laboratories plans to ramp up manufacturing capacity for its lower-cost continuous glucose monitor, the FreeStyle Libre, by three to five times in the next few years, aiming to reach millions more patients worldwide, the company told Reuters.

Abbott device helps in cutting blood sugar in type 2 diabetics: study

Insulin-dependent patients with type 2 diabetes saw a significant drop in their blood sugar levels after wearing Abbott Laboratories Inc's continuous glucose monitoring system for three months compared with when they were not using the device, researchers said on Saturday.

CORRECTED-Abbott device helps in cutting blood sugar in type 2 diabetics - study (June 8)

June 8 Insulin-dependent patients with type 2 diabetes saw a significant drop in their blood sugar levels after wearing Abbott Laboratories Inc's continuous glucose monitoring system for three months compared with when they were not using the device, researchers said on Saturday.

Select another date: